Effects of Empagliflozin on Symptoms, Physical Limitations and Quality of Life in Patients Hospitalized for Acute Heart Failure - Results From the EMPULSE Trial

• Tipo: Artigo em Revista Científica Internacional
• Data: 2022

Autores

Kosiborod, MN (Autor) Outra; Angermann, CE (Autor) Outra; Collins, SP (Autor) Outra; Teerlink, JR (Autor) Outra; Ponikowski, P (Autor) Outra; Biegus, J (Autor) Outra; Comin-Colet, J (Autor) Outra; Ferreira, JP (Autor) FMUP; Mentz, RJ (Autor) Outra; Nassif, ME (Autor) Outra; Psotka, MA (Autor) Outra; Tromp, J (Autor) Outra; Brueckmann, M (Autor) Outra; Blatchford, JP (Autor) Outra; Salsali, A (Autor) Outra; Voors, AA (Autor) Outra

Revista

Título: Circulation

ISSN: 0009-7322

Editora: Wolters Kluwer Health

Outras Informações

ID Authenticus: P-00W-TW0

DOI: 10.1161/circulationaha.122.059725

Abstract (EN): <jats:p> <jats:bold>Background:</jats:bold> Patients hospitalized for acute heart failure (AHF) experience poor health status, including high burden of symptoms and physical limitations, and poor quality of life. Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve health status in chronic HF, but their impact on these outcomes in AHF are not well characterized. We investigated the effects of the SGLT2 inhibitor empagliflozin on symptoms, physical limitations and quality of life, using the Kansas City Cardiomyopathy Questionnaire (KCCQ) in the EMPULSE trial. </jats:p> <jats:p> <jats:bold>Methods:</jats:bold> Patients hospitalized for AHF were randomized to empagliflozin 10 mg daily or placebo for 90 days. The KCCQ was assessed at randomization and 15, 30 and 90 days. The effects of empagliflozin on the primary endpoint of clinical benefit (hierarchical composite of all-cause death, heart failure events, and a¿5-point or greater difference in KCCQ Total Symptom Score (TSS) change from baseline to 90¿days) were examined <jats:italic>post hoc</jats:italic> across the tertiles of baseline KCCQ-TSS. In pre-specified analyses, changes (randomization to Day 90) in KCCQ domains, including TSS, Physical Limitations (PLS), quality of life (QoL), clinical summary (CSS) and overall summary (OSS) scores were evaluated using a repeated measures model. </jats:p> <jats:p> <jats:bold>Results:</jats:bold> In total, 530 patients were randomized (265 each arm). Baseline KCCQ-TSS was low overall (mean, SD; 40.8, 24.0 points). Empagliflozin-treated patients experienced greater clinical benefit across the range of KCCQ-TSS, with no treatment effect heterogeneity (win ratio [95% CIs] from lowest to highest tertile: 1.49 [1.01, 2.20], 1.37 [0.94, 1.99], and 1.48 [1.00, 2.20], respectively; <jats:italic>P</jats:italic> for interaction=0.94). Beneficial effects of empagliflozin on health status were observed as early as 15 days and persisted through 90 days, at which point empagliflozin-treated patients experienced a greater improvement in KCCQ TSS, PLS, QoL, CSS and OSS (placebo-adjusted mean differences (95% CI): 4.45 (0.32, 8.59), <jats:italic>P</jats:italic> =0.03; 4.80 (0.00, 9.61), <jats:italic>P</jats:italic> =0.05; 4.66 (0.32, 9.01), <jats:italic>P</jats:italic> =0.04; 4.85 (0.77, 8.92), <jats:italic>P</jats:italic> =0.02; and 4.40 points (0.33, 8.48), <jats:italic>P</jats:italic> =0.03, respectively). </jats:p> <jats:p> <jats:bold>Conclusions:</jats:bold> Initiation of empagliflozin in patients hospitalized for AHF produced clinical benefit regardless of the degree of symptomatic impairment at baseline; and improved symptoms, physical limitations and quality of life, with benefits seen as early as 15 days and maintained through 90 days. </jats:p>

Idioma: Inglês

Tipo (Avaliação Docente): Científica